1
Jean Pierre Sommadossi, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes: Compounds and pharmaceutical compositions for the treatment of viral infections. Idenix Pharmaceuticals, L Université Montpellier II, Jones Day, May 31, 2011: US07951789 (28 worldwide citation)

Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.


2
Jean Pierre Sommadossi, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes: Compounds and pharmaceutical compositions for the treatment of viral infections. Idenix Pharmaceuticals, L Université Montpellier II, Jones Day, March 8, 2011: US07902202 (16 worldwide citation)

Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.


3
Jean Pierre Sommadossi, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes: Compounds and pharmaceutical compositions for the treatment of viral infections. Idenix Pharmaceuticals, Centre National de la Recherche Scientifique, Universite Montpellier II, Jones Day, April 8, 2014: US08691788 (12 worldwide citation)

Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.


4
Cyril B Dousson, David Dukhan, Christophe Claude Parsy, Claire Pierra, Francois Rene Alexandre, Guillaume Brandt, Daniel Da Costa, Houcine Rahali, Jean Laurent Paparin, Michel Derock, Thierry Convard, Dominique Surleraux: 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors. Idenix Pharmaceuticals, Jones Day, January 29, 2013: US08362068 (10 worldwide citation)

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host ...


5
Dominique Surleraux, Cyril B Dousson, David Dukhan, Claire Pierra: Compounds and pharmaceutical compositions for the treatment of viral infections. Idenix Pharmaceuticals, Jones Day, February 10, 2015: US08951985 (4 worldwide citation)

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.


6
Alistair James Stewart, Adel M Moussa, Benjamin Alexander Mayes, Francois Rene Alexandre, Dominique Surleraux, Christophe Claude Parsy, Claire Pierra, David Dukhan, Gilles Gosselin: 3′-deoxy nucleosides for the treatment of HCV. IDENIX PHARMACEUTICALS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNIQUES, Squire Patton Boggs, April 12, 2016: US09309275 (1 worldwide citation)

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral a ...


7
Christophe Claude Parsy, Francois Rene Alexandre, Cyril B Dousson, David Dukhan, Claire Pierra, Dominique Surleraux, Benjamin Alexander Mayes, Adel M Moussa, Alistair James Stewart: 3′,5′-cyclic phosphoramidate prodrugs for HCV infection. IDENIX PHARMACEUTICALS, Squire Patton Boggs, August 18, 2015: US09109001 (1 worldwide citation)

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral a ...


8
Cyril Dousson, Claire Pierra, Jean Francois Griffon, Frederic Leroy, Jean Laurent Paparin, David Dukhan, Dominique Surleraux: Phosphothiophene and phosphothiazole HCV polymerase inhibitors. Idenix Pharmaceuticals, Jones Day, June 5, 2012: US08193372 (1 worldwide citation)

Provided herein are phosphothiophene and phosphothiazole compounds, for example, of any of Formulae I, IA, IIA, IIIA, IVA, VA, VIA, VIIA, IB, IIB, IIIB, IVB, VB, VIB and VIIB disclosed herein, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided a ...


9
Cyril Dousson, Dominique Surleraux, Jean Laurent Paparin, Claire Pierra, Arlène Roland: Phosphadiazine HCV polymerase inhibitors IV. Idenix Pharmaceuticals, Jones Day, April 26, 2011: US07932240 (1 worldwide citation)

Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas IV, IV′, I″, II″, or IVa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in nee ...


10
Dominique Surleraux, Cyril B Dousson, Gilles Gosselin, David Dukhan, Claire Pierra, Jerome Peyronnet: Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections. IDENIX PHARMACEUTICALS, Squire Patton Boggs, August 2, 2016: US09403863

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. I ...